Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors
Third Cell Therapy For Lymphoma Approved In The US
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.
You may also be interested in...
The CAR-T therapy met the primary endpoint of improvement in event-free survival in a Phase III trial evaluating Breyanzi as a second-line alternative to stem cell transplant in large B-cell lymphoma.
Giving cell therapies as outpatient rather than inpatient treatments could be a way around the need for bundled payments, but it’s not universally applicable.
Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.